Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum subsp. infantis SINE006
- Development stage
- Phase 4
- Lead developer
- Chinese PLA General Hospital
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
bifidobacterium longum subsp. infantis SINE006 is a specific probiotic strain of the Bifidobacterium genus. It is currently being evaluated in a Phase 4 clinical trial by the Chinese PLA General Hospital for the treatment of idiopathic short stature (ISS) in children aged 3 to 8 years. The strain is administered orally, typically in combination with organic calcium supplements (such as calcium citrate and fruit-derived calcium). The therapeutic rationale is based on the modulation of the gut microbiota to enhance nutrient absorption and potentially influence the gut-bone axis and systemic growth factors such as insulin-like growth factor 1 (IGF-1), thereby promoting linear growth and bone maturation in children with ISS. The study also explores potential synergy with growth hormone therapy.
- Other names
- Bifidobacterium longum subsp. infantis SINE006
Beyond the preview
Go deeper on bifidobacterium longum subsp. infantis SINE006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum subsp. infantis SINE006.